These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8306541)

  • 1. Hereditary breast-ovarian cancer: how can we use the new DNA markers to improve patient management?
    Narod S
    Clin Invest Med; 1993 Aug; 16(4):314-7. PubMed ID: 8306541
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular markers of breast and ovarian cancer.
    Steel CM
    Dis Markers; 1991; 9(3-4):213-23. PubMed ID: 1813211
    [No Abstract]   [Full Text] [Related]  

  • 3. Bibliography. Current world literature. Model systems.
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):74-89. PubMed ID: 18197010
    [No Abstract]   [Full Text] [Related]  

  • 4. DNA methylation markers: a versatile diagnostic tool for routine clinical use.
    Lesche R; Eckhardt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):222-30. PubMed ID: 17608020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study.
    Lynch HT; Watson P; Conway TA; Lynch JF; Slominski-Caster SM; Narod SA; Feunteun J; Lenoir G
    Arch Intern Med; 1993 Sep; 153(17):1979-87. PubMed ID: 8357282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspiration cytology of ovarian tumors.
    Granados R
    Curr Opin Obstet Gynecol; 1995 Feb; 7(1):43-8. PubMed ID: 7742515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
    Couch FJ; Garber J; Kiousis S; Calzone K; Hauser ER; Merajver SD; Frank TS; Boehnke M; Chamberlain JS; Collins FS
    J Natl Cancer Inst Monogr; 1995; (17):9-14. PubMed ID: 8573462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The chance of breast carcinoma and related carcinomas in a positive family anamnesis. Landelijke Werkgroep Erfelijk Mammacarcinoom van de Stichting Opsporing Erfelijke Tumoren].
    Oosterwijk JC; Sijmons RH; Menko FH; Chorus AM; Rookus MA
    Ned Tijdschr Geneeskd; 1995 Mar; 139(9):423-8. PubMed ID: 7891763
    [No Abstract]   [Full Text] [Related]  

  • 9. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of multiple markers to enhance clinical utility.
    Mercer DW
    Immunol Ser; 1990; 53():39-54. PubMed ID: 2100569
    [No Abstract]   [Full Text] [Related]  

  • 11. Single cell multiple biomarker analysis in archival breast fine-needle aspiration specimens: quantitative fluorescence image analysis of DNA content, p53, and G-actin as breast cancer biomarkers.
    Rao JY; Apple SK; Hemstreet GP; Jin Y; Nieberg RK
    Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1027-33. PubMed ID: 9829712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of tumor markers in breast cancer management.
    Lenahan C; Garibyan L; Pories S
    Curr Surg; 2004; 61(6):532-7. PubMed ID: 15590016
    [No Abstract]   [Full Text] [Related]  

  • 13. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
    Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
    Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening of inherited breast cancer with DNA markers.
    Lalle P; Bignon YJ; Stoppa-Lyonnet D; Narod SA; Mazoyer S; Rio P; Courjal F; Bartholin P; Sobol H
    Lancet; 1993 May; 341(8857):1422. PubMed ID: 8098837
    [No Abstract]   [Full Text] [Related]  

  • 15. [New studies on breast cancer to predict disease outcome and clinical use of these new tests].
    Kallioniemi OP; Holli K; Visakorpi T; Koivula T; Helin H; Isola J
    Duodecim; 1991; 107(11):907-16. PubMed ID: 1364737
    [No Abstract]   [Full Text] [Related]  

  • 16. Putrescine, DNA, RNA and protein contents in human uterine, breast and rectal cancer.
    Bandopadhyay M; Ganguly AK
    J Postgrad Med; 2000; 46(3):172-5. PubMed ID: 11298463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospectively detected cancer in familial breast/ovarian cancer screening.
    Dørum A; Heimdal K; Løvslett K; Kristensen G; Hansen LJ; Sandvei R; Schiefloe A; Hagen B; Himmelmann A; Jerve F; Shetelig K; Fjaerestad I; Tropé C; Møller P
    Acta Obstet Gynecol Scand; 1999 Nov; 78(10):906-11. PubMed ID: 10577622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
    Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hereditary cancer of the breast and ovary].
    Díez Gibert O; Machuca Cordano I; Navarro MA
    Med Clin (Barc); 1998 Feb; 110(5):199. PubMed ID: 9547728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.